A

AI Research

Agilent Acquires Biocare Medical for $950M → Launches Advanced Therapeutics CDMO, Stock -15% YTD

Agilent Technologies announced the acquisition of Biocare Medical for $950 million to strengthen its pathology reagents and workflow solutions business, while launching an Advanced Therapeutics CDMO service, though the stock is down approximately 15% year-to-date reflecting life science tools end market softness. Analysts hold a Buy consensus with an average price target of $161.20, viewing the stock pullback as an attractive entry point given Agilent's diversified analytical instruments and life science portfolio. Risks include continued pharmaceutical and biotech customer spending caution, academic research budget pressures, and integration risk from the Biocare acquisition.